Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
6.53
+0.12 (1.87%)
Jul 30, 2026, 11:54 AM EDT - Market open
Upstream Bio Market Cap
Upstream Bio has a market cap or net worth of $355.36 million as of July 30, 2026. Its market cap has decreased by -52.71% in one year.
Market Cap
355.36M
Enterprise Value
55.37M
1-Year Change
-52.71%
Ranking
Category
Stock Price
$6.53
ChartMarket Cap Chart
Since the IPO on October 11, 2024, Upstream Bio's market cap has decreased from $393.35M to $355.36M, a decrease of -9.66%. That is a compound annual growth rate of -5.49%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 30, 2026 | 355.36M | -75.78% |
| Dec 31, 2025 | 1.47B | 66.51% |
| Dec 31, 2024 | 881.13M | 124.01% |
| Oct 11, 2024 | 393.35M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| X4 Pharmaceuticals | 373.51M |
| DiaMedica Therapeutics | 366.41M |
| Rocket Pharmaceuticals | 359.25M |
| Fennec Pharmaceuticals | 357.62M |
| Lexeo Therapeutics | 356.88M |
| Abeona Therapeutics | 350.52M |
| Palisade Bio | 348.03M |
| Zentalis Pharmaceuticals | 327.46M |